MIRA Pharmaceuticals
MIRA
26 hedge funds and large institutions have $2.19M invested in MIRA Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 6 reducing their positions, and 4 closing their positions.
86% more capital inflows, than outflows
Capital inflows: $349K | Capital outflows: $188K
0.38% more ownership
Funds ownership: 5.13% → 5.51% (+0.38%)
0% more funds holding
Funds holding: 26 → 26 (0)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
0% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$134K |
| 2 |
CAPTRUST Financial Advisors
Raleigh,
North Carolina
|
+$91.7K |
| 3 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
+$58.5K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$18.9K |
| 5 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$18.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Suncoast Equity Management
Tampa,
Florida
|
-$97K |
| 2 |
Vanguard Global Advisers
Malvern,
Pennsylvania
|
-$26K |
| 3 |
Frec Markets Inc
San Francisco,
California
|
-$23.5K |
| 4 |
XTX Topco
George Town,
Cayman Islands
|
-$21.4K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$6.66K |
MIRA Hedge Fund Activity: Q2 2026 in Review
26 of the 8,360 institutional investors tracked by Wall St. Rank reported a position in MIRA Pharmaceuticals (MIRA) for Q2 2026, worth a combined $2.19M — down 4.6% from $2.3M a quarter earlier.
Fund positioning in MIRA was balanced in Q2 2026: 4 funds opened new positions, 4 closed out, 6 added to existing stakes and 6 trimmed.
The largest buyer was BlackRock, adding an estimated $134K. The largest seller was Suncoast Equity Management, exiting entirely with an estimated $97K sold.
- 26 institutional investors held MIRA Pharmaceuticals (MIRA) as of Q2 2026, unchanged from Q1 2026.
- Funds reported $2.19M of MIRA Pharmaceuticals stock for Q2 2026, down 4.6% quarter-over-quarter.
- 4 funds opened new MIRA Pharmaceuticals positions in Q2 2026 and 4 closed out, a net change of 0 holders.
- The largest MIRA Pharmaceuticals buyer in Q2 2026 was BlackRock, an estimated $134K added.
- The largest MIRA Pharmaceuticals seller in Q2 2026 was Suncoast Equity Management, an estimated $97K sold.
Based on aggregated 13F filings for Q2 2026.